Companies in #B-cell Malignancies
Found 2 companies operating in this sector.
BeiGene (NASDAQ: BGNE; HKEX: 06160) is a global oncology company developing innovative, affordable therapies for cancer patients worldwide. Best known for Brukinsa (zanubrutinib), a BTK inhibitor approved for multiple B-cell malignancies. Committed $300M in 2026 to expand US manufacturing capacity.
BeOne Medicines is a global oncology company that discovers and develops innovative medicines intended to improve the lives of patients worldwide. The company markets BRUKINSA (zanubrutinib), a BTK inhibitor approved for B-cell malignancies.